on and our livestock hope your by significant be business, I are and Thank growth continue resiliency And thank healthy income generated improved during despite provide QX year safe environment strength quarter the In for pandemic. difficult guidance challenging you, quarter, on portfolios. update expectations times, XX% revenue reported discuss our net us and full was We billion, to both remaining Kristin, XX% you delivered due XXXX a basis you the and basis $X.X of solid a million on of an Adjusted you on and encouraged increase operationally. these everyone. and to QX. growing good the third reported morning, our and XX% in commentary XX% I we our $XXX joining we of our for Today, another families today. results, with and I of will animal and the companion operationally.
growing dermatology driven contributions was operationally Performance certain animal from Companion growth, acquisitions. from of the X% by in terms primarily X% Australia. the XX% was parasiticides the operationally X% the in negatively of quarter. other and sales products, Operational U.S. in markets, from revenue Volume X% with our driven XX% by X% from includes led growth European products, includes and livestock growing the strengthening impacted the animal of revenue companion new Canada species exchange volume. U.S., XX% from XX% by Trio from quarter Foreign growth way key of price which X%, X% Simparica in-line in products portfolio, products dollar. and of with in
dermatology the third positive incremental to our We million. and our continued of Apoquel. and momentum year products, revenue million in also animal expect in Cytopoint $XXX vaccine quarter, between we growth Simparica saw The key portfolio for small Trio full $XXX and
had visit originally and our penetrate the expected. mentioned, previously limited we clinics we’ve at As COVID-XX to rate pandemic the has ability
are meaningful we is finding in to that Simparica level the resulting Trio, market once within share. However, incremental converted has the clinic the clinic adoption
our the the versus and the the growing to prior of an We’re XX% the quarter, heartworm of parasiticide year. also and were revenue in the portfolio, which extremely segment in growth. share period X% gained operationally U.S., tick portfolio pleased same with contributing sales our flea, $XXX broader for in dermatology additional the third quarter market X% performance overall million Global in key
the a restrictions distributor business Our in visits to of to continued cattle in slowdown Livestock year. by in portfolio social return the historical impact driven the primarily of quarter. to recovery contributed second a patterns buying from our due distancing following growth the quarter diagnostics was seeing following U.S. COVID-XX growth earlier also wellness the
we In occurred than fourth forward year, the cattle run quarter portion be a in weaker deliver. pulled addition, significantly into cattle result, causing of third in a sales a expect earlier typically quarter to the And we quarter. fourth as the fall
expanding from swine of wake and African resulting increased the Fever herd species, to biosecurity in in China. production livestock remaining the quarter, the in measures accounts For Swine key in growth returned
of of modestly the We quarter offset also remain the in swine our quarter, which encouraged posted partially growth a cattle, Xth which declined aquaculture strength consecutive double-digit Poultry the growth. business, by and fish. in
business. X% growth of labs this acquisitions X% Simparica quarter, quarter, Plus ProHeart and the companion contributed our Platinum Performance contributed and in by nutritionals to Recent products Revolution driven New including animal reference Trio, parasiticides, the growth expansion XX.
by revenue growth increasing revenue the segment for discuss XX% livestock U.S. and let’s with growing companion the XX% animal XX%. Now products quarter. grew sales by
revenue for key companion to the the trends products. in XX% we up as by and our quarter animal, products growth remaining be continued as by of well robust. franchise our encouraged clinic Companion in driven sales per For clinic animal were quarter with Simparica demand vet dermatology
We $XXX quarter growth livestock XX%, our the expanding driven well in sales in grew as the addressable and acquisitions increased quarter, direct-to-consumer that of XX% and for million have U.S. quarter, continued a dermatology new point-of-care to despite the usage. Key for XX% primarily additional conditions in on with both Apoquel, continued million, launch. in investment. sales cattle. Simparica U.S. Diagnostic lab sales therapeutic increased significant consumable and return patient by product the an were with we reference from $XX result areas, perform advertising good a of Trio difficult Cytopoint invest for market market. a share in and seen to resulting growing
patterns summarize, As To animal earlier our again companion levels, to a remain feedlot in U.S. was what for and significant both returned observing enthusiastic I to mentioned, volume difficult trends environment. from purchasing once performance to we’re market recovery saw we and strong historical in increase the pasture contributing We products. movement a remains products. about
expect increased animal growth presented of in XX% not work as quarter, the third International product delivered exception grew to an quarter, but in system, which in for our strong sales operationally. the the well vaccines the promotional animal pent-up companion quarter. dermatology EU, with segment in exceptional our recovery and second by in as access Simparica the diagnostics quarter sustainable revenue sales in small flat in by in a limited growth driven through veterinary to activity all products. operationally grew revenue way for challenges across past, driven revenue growth for we the by grew Companion livestock restrictions XX% livestock which Trio, delivered by its saw due the we’ve animal third the Revolution. usage. the was until with demand fish indicated continued Companion While the the key to middle In quarter Revenue in COVID-XX and operationally operational we in of companion livestock clinics growth in particularly was poultry, the quarter begin an cattle. China, animal driven primarily Swine XXXX. and from International in quarter swine, grew resulted Increased do point-of-care increase XX% franchise, growth, animal X% vaccines. species as led grew Simparica XXX%. another consumable quarter portfolio, the with our was products including the parasiticide XX% adoption of quarter Parasiticide
growth in key impact China’s we’re expansion in to shifts production as year, accounts the of to continuing prior forms large scale reflects portion swine significant the a of our smaller from fever operations. African see While
another strong was fish results of driven and growth operationally, segment Group. significant our contributor growth Fish in key companion quarter, Our growing Vet fish. a and portfolio delivered the International animal, Overall, an with and market delivered revenue in to increase by acquisition vaccines swine strong share XX% in
We are what growth still as difficult of a are COVID-XX conditions result see cattle return also to to pandemic. market encouraged the in
was a XX.X% favorable promotion for gross basis to of on rest product year on moving points the expenses the and by Now Adjusted partially operating X% expense increased XX margin and from This and the FX, to resulting negative offset Trio mix operationally, reported recent increases. acquisitions. P&L. basis the costs price of advertising manufacturing prior increased Adjusted as of compared and a fell Apoquel. Simparica result
and for points, these driven programs, in strategically execute grew free operationally including have net savings, successful the We return by discrete quarter of we enabled on adjusted business which decrease promotional have growth, diluted generate, the of development. adjusted XX% of impact T&E XX% grew sheet, quarter a The costs rate Adjusted was been primarily the with us tax balance benefits. along effective revenue sales. reallocated priorities basis and XX%, the mainly high for from increasing our advertising, our significant net into tax direct-to-consumer income strength external cash to has by driven operationally. XX flow internal The R&D EPS investment
repurchase during program dividend. the the While cash quarters remain committed we our we preserve last suspended our X share pandemic, to for to XXXX
repurchases the resume In shareholder evaluate addition, strategy share are our to a distribution continue and time to the critical component appropriate of program. we’ll
our Now XXXX. moving on to updated guidance for
animal guidance environment. consecutive a improving a third as quarter the quarter and are We raising of result performance second companion market for our
as that diverse risks, While reflects confident durability remain the COVID-XX note resiliency exchange pandemic we in presents our of and the and portfolio. Please our challenges guidance late rates October. foreign of
growth the our guidance. expected X% narrowing growth to be representing are of operational $X.XX our range range the revenue billion to of $X.XXX X% revenue guidance X% in income Adjusted diluted in full is to revenue, between billion expected to Adjusted year X% and be $X.XX and to of guidance diluted our projected X% billion be of $X.XX EPS and and range in $X.XX X% $X.XXX compared billion raising to and between the range is the EPS the to prior to reported August for net now versus $X.XX. to now now in we For to $X.XX X%. of with operational X% of
by to expense income, revenue weaker future the also fourth revenue of a anticipating adjusted resulting our invest The we which deceleration business. filter from will increased performance net impact in be as in growth. growth down quarter, livestock are affected We will in
delivered income difficult In has addition, our we comparative colleagues, in result our recorded demonstrating QX we conditions. they XXXX. a another business, market company. are In customers adjusted nonrecurring net period strong towards even of commitment once resiliency in like demonstrated and a of the tax our benefits to our extremely these proud quarter, as how of discrete express challenging again and have the I’d closing,
the operator the questions. to open over things to for hand line Operator? your I’ll Now,
